Navigation Links
Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
Date:9/23/2011

tem (CNS) depressants.  Additive CNS effects are expected when used with alcohol, benzodiazepines, other opioids, or illicit drugs.
  • QTc Prolongation: Avoid in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic medications.
  • Head Injury:  Butrans may worsen increased intracranial pressure and obscure its signs, such as level of consciousness or pupillary signs.
  • Hypotensive Effects: Butrans may cause severe hypotension.  Use with caution in patients at increased risk of hypotension and in patients in circulatory shock.
  • Application Site Skin Reactions: In rare cases, severe application site skin reactions with signs of marked inflammation including "burn," "discharge," and "vesicles" have occurred.
  • Anaphylactic/Allergic Reactions: Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience.
  • Use in Pancreatic/Biliary Tract Disease and Other Gastrointestinal Conditions: Use with caution in patients with biliary tract disease, including acute pancreatitis.  Ileus may occur.  Monitor for decreased bowel motility.

    • Adverse Event InformationThe most common adverse events (greater than or equal to 5%) reported by patients treated with Butrans in clinical trials were nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.  The most frequently occurring application site skin reactions were application site pruritus, erythema, rash and irritation.  In rare cases, severe application site skin reactions with signs of marked inflammation including "burn," "discharge," and "vesicles" have occurred.

    Butrans Transdermal System Dosages Three strengths of Butrans are commercially available by
    '/>"/>

    SOURCE Purdue Pharma L.P.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AIMs Program for Improving Echocardiography Appropriateness Yields Impressive Results
    2. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
    3. Accuray Announces Results for Fourth Quarter and Fiscal Year 2011
    4. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
    5. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
    6. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
    7. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
    8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
    9. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
    10. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
    11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... , June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a general corporate update in conjunction ... on Tuesday, June 25 at 2:10 p.m. Pacific Time in ... for the meeting is as follows: 2:00 p.m. – 2:10 ... as of April 26, 2013) 2:10 p.m. – 3:15 p.m. ...
    (Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
    (Date:6/17/2013)... June 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a preliminary prospectus supplement to its effective ... a similar filing with securities regulatory authorities in each of ... with a public offering of its common shares to raise ... The Company will also grant to the underwriters of the ...
    Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
    (Date:6/19/2013)... 2013 In honor of women everywhere, ... providing information that women can use to improve their ... women should pay close attention to their health, as ... changes a woman’s body undergoes while pregnant can increase ... says Dr. Ray Workman, a leading vein doctor at ...
    (Date:6/19/2013)... Washington, DC (PRWEB) June 19, 2013 ... experiment in the history of managed care. As ... find coverage through the new state-based and federally ... requirements for essential health benefits, and examples of ... some states, industry-leading health business information publisher Atlantic ...
    (Date:6/19/2013)... (PRWEB) June 19, 2013 Scott Tischler of ... curb this swim suit season. , 1.    The very first thing ... big tall glass of ice cold water. The body is ... water. This will keep the body hydrated and will also ... body has to raise the temperature of the water to ...
    (Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
    (Date:6/19/2013)... Transvaginal mesh lawsuits are moving along in the New ... how to handle evidence in the C.R. Bard lawsuits, specifically ... components removed from patients. The Rottenstein Law Group LLP maintains ... about the device and a guide on how to file ... the medical facilities that currently hold them and are to ...
    Breaking Medicine News(10 mins):Health News:Novant Health Vein Specialists Promotes Women’s Health with Social Media Campaign 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
    ... Mich., April 3 Recently, researchers at the ... Business conducted a study of U.S. hospitals and discovered ... a year. The study recommended solutions, including location-based technology, ... results of this study come at a time when ...
    ... Bertalan Mesko, medical blogger and health 2.0 consultant ... The Netherlands at a Health 2.0 event where he focused ... E-patients are patients who communicate with their doctors via webcam ... are more up-to-date than their own doctors because they use ...
    ... President of the California Association of Health Underwriters ... today to join him in demanding that Congress ... health care reform in the partisan environment of ... of Health Underwriters, the California Association insists that ...
    ... neurodegenerative disease , , FRIDAY, April 3 (HealthDay News) -- ... prevent brain cells from falling victim to the ravages ... the preliminary stages, and the researchers don,t know if ... disease expert said the findings could lead to a ...
    ... computer based model that aids them in discriminating between ... performed at the University Of Wisconsin School of Medicine, ... group, including radiologists and industrial engineers, led by Elizabeth ... PhD. , "The computer based model ...
    ... Boston University School of Medicine,s (BUSM) New England ... with healthy aging and longevity amongst the children ... with scientists from the National Institute on Aging. ... Journal of the American Geriatrics Society . ...
    Cached Medicine News:Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 2Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 3Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 4Health News:Scientists Uncover New Weapon Against Huntington's 2Health News:Computer based model helps radiologists diagnose breast cancer 2Health News:Researchers identify personality traits 2
    ... collect sample, pipette into testing wells ... FDA 510K cleared multiple drug screen ... both drugs and adulterants. It can ... (5) drugs and can be accompanied ...
    ... Glucose Monitoring System is a patient insertable short-term ... the DexCom STS Receiver., The DexCom STS Sensor ... the DexCom STS Applicator by the user or ... held in place by an adhesive to the ...
    ... routine Holter,monitoring, the Burdick Vision ... a,practical, no-nonsense diagnostic tool ideal,for ... This highly accurate and,easy-to-use system ... configurations at a price even ...
    ... PC-based ECG diagnostics complements transition to ... the incorporation of computer-based technology into ... diagnostic instrumentation have developed. Burdick's Universal ... EMRs making it the ideal choice ...
    Medicine Products: